Contact Us
Contact Us
Pharmaceutical
Drug development timelines determine competitive position. First to market captures the market. Second place isn’t an option.
If your organization manages clinical trials, regulatory submissions, or quality systems on Lotus Notes and Domino, you’re executing research on infrastructure that creates friction exactly where you need velocity. Your competitors with modern systems are executing faster.
The constraint goes beyond technical challenges. Pharmaceutical systems require validation under FDA, Health Canada, and EMA frameworks. You can’t simply rebuild. You need migration approaches that maintain the validation state regulators require while eliminating the platform limitations that slow research execution.
We’ve worked with pharmaceutical companies and biotech firms where regulatory compliance was scrutinized intensely. Validation requirements added complexity that most IT projects never face. Let’s talk about whether we can help with your situation.
What Pharmaceutical Leaders Tell Us
Quality assurance directors, regulatory affairs leaders, and CIOs in pharma face pressure that’s unique even among highly regulated industries. You need to demonstrate data integrity, maintain proper audit trails, and prove systematic control over processes—while executing research fast enough to maintain a competitive position.
Regulatory Compliance Creates Binary Outcomes
Pharmaceutical compliance doesn’t work on a curve. You either meet the standard or you don’t. FDA and Health Canada audits don’t accept workarounds. EMA inspections don’t waive requirements because you’re planning to modernize eventually.
Legacy Notes and Domino environments struggle with requirements that didn’t exist when these platforms were architected. What regulators expect for 21 CFR Part 11 compliance has evolved. What inspectors look for during data integrity investigations has evolved. What validation documentation must demonstrate has evolved. The platforms haven’t kept pace.
Quality assurance leaders are building modernization business cases to eliminate compliance exposure created by legacy platforms.
Intellectual Property Attracts Sophisticated Threats
Clinical trial results could inform competitive research strategies. Manufacturing processes represent decades of optimization. Formulation details constitute core intellectual property.
Pharmaceutical data attracts nation-state actors, industrial espionage operations, and ransomware specifically designed to disrupt research organizations. Legacy platforms lack the security architecture required to protect this data. Advanced persistent threats, sophisticated intrusion campaigns, and targeted attacks all demand defensive capabilities that can’t be retrofitted into twenty-year-old systems.
Platform Limitations Slow Research Down
Research teams spend time fighting technology constraints instead of analyzing results. Regulatory affairs groups manually compile submission packages that modern systems could generate systematically. Clinical operations coordinators work around system limitations instead of executing trials efficiently.
These productivity problems create competitive disadvantages that compound while competitors with modern infrastructure reach regulatory milestones ahead of you.
How We Help Pharmaceutical Organizations Modernize
Pharmaceutical migration requires understanding that validation can’t be compromised. Regulatory compliance must be maintained. Data integrity is absolutely non-negotiable throughout transitions.
Revive: Maintaining Validation State During Migration
Pharmaceutical systems require validation under FDA, Health Canada, EMA, and other regulatory frameworks. Revive handles Lotus Notes migration while maintaining the validation state required by regulators.
Clinical protocols, quality processes, and regulatory submission workflows are modernized—React interfaces, Java business logic, and SQL databases with proper audit trails—while preserving the business logic and data integrity referenced in validation documentation.
We migrate in parallel with existing validated systems. Your clinical trials continue under current protocols. Your quality systems remain operational and compliant. Your regulatory submissions proceed without interruption.
How does validation work for your specific environment? That depends on your systems and validation strategy. We can discuss the approach after understanding your requirements.
AppAnalyzer: Understanding Which Systems Require Revalidation
Before committing to migration, you need to understand which applications are GxP-critical and require full revalidation. Are there any that can follow streamlined approaches under risk-based validation principles? Which might be retired rather than migrated?
AppAnalyzer provides this analysis at no cost. The data helps you build migration plans that satisfy quality assurance requirements and regulatory expectations.
Dcom: Meeting Extended Retention Requirements
Pharmaceutical regulations mandate extended data retention—typically fifteen years or longer for clinical trial data, potentially permanent for commercial product records. Even after migrating active applications, you need access to historical data with demonstrated integrity.
FDA and Health Canada investigators request historical batch records. You respond to post-market safety inquiries. Clinical trial participants return for long-term follow-up. All of these scenarios require you to retrieve original data with proven integrity.
Dcom converts legacy data to validated, searchable archives that preserve data integrity and ALCOA+ compliance, maintain complete audit trails, and remain accessible through standard interfaces.
Why Pharmaceutical Companies Work With Us
Pharmaceutical migration requires more than technical capability. It requires understanding the regulatory environment, the validation implications of system changes, the data integrity principles that must be maintained, and the competitive pressure to execute faster than you’re currently able.
Clinical operations leadership wants systems that accelerate trial execution. Regulatory affairs wants technology that simplifies submission processes. Quality assurance wants demonstrated compliance improvements. Executive leadership wants a competitive time-to-market.
We’ve worked with pharmaceutical organizations—from emerging biotech companies managing early-stage trials to established firms with global development programs—where these same demands existed.
Can we help with your specific situation? Schedule a call. We’ll tell you honestly whether our approach makes sense for your requirements.